Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: doxorubicin hydrochloride|DRUG: cyclophosphamide|BIOLOGICAL: filgrastim|DRUG: paclitaxel albumin-stabilized nanoparticle formulation|BIOLOGICAL: trastuzumab|OTHER: laboratory biomarker analysis|PROCEDURE: quality-of-life assessment
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)